Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glycosaminoglycan Polysulfate→

Glycosaminoglycan Polysulfate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9082-07-9
Molecular formula
Not available
Molecular weight
Not available
Drug class
Heparinoid glycosaminoglycantopical anti-inflammatory and antiexudative agent
Mechanism of action
Mucopolysaccharide polysulfate has local heparinoid, anti-inflammatory, anti-exudative and fibrinolytic properties. The UK product information describes weak inhibition of prostaglandin E2 synthesis, an indirect effect on leukotriene B4, potentiation of urokinase activity and inhibition of hyaluronidase.
Indications / reported uses
  • Used as a component of topical salicylic acid/mucopolysaccharide polysulfate products for symptomatic relief of muscular pain and stiffness, sprains, strains and pain due to rheumatic and non-serious arthritic conditions. It is not a stand-alone systemic anticoagulant indication.

Sources: https://www.medicines.org.uk/emc/product/1352/smpc · https://www.medicines.org.uk/emc/product/1351/smpc · https://www.ndf.gov.sg/about-drugs/active-ingredient/m00249/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glycosaminoglycan Polysulfate Environmental Risk Assessment (ERA) (the Glycosaminoglycan Polysulfate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.